This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About MEI Pharma Stock (NASDAQ:MEIP) Get MEI Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.78▼$5.2852-Week Range N/AVolume3.98 million shsAverage Volume1.15 million shsMarket Capitalization$104.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MEI Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company’s lead programs include pracinostat, an oral histone deacetylase inhibitor being studied in combination with azacitidine for acute myeloid leukemia, ME-401 (umbralisib), a next-generation PI3K-delta inhibitor targeting various B-cell malignancies, and CPI-1205, an EZH2 inhibitor under evaluation in both hematologic and solid tumor indications. MEI Pharma’s pipeline reflects a strategic emphasis on epigenetic and signal-transduction pathways that have the potential to address critical unmet needs in oncology. Headquartered in San Diego, California, MEI Pharma operates in key clinical research geographies across North America and Europe, collaborating with academic institutions and contract research organizations to advance its clinical trials. The company leverages a combination of in-house discovery capabilities and external partnerships to optimize its development candidates, with a focus on robust study designs and expedited regulatory pathways where warranted. MEI Pharma’s approach aims to move promising compounds efficiently through early- to late-stage trials and ultimately into commercialization. MEI Pharma was incorporated in the early 2000s and has since evolved into a specialized oncology developer with a seasoned management team. Vamsi N. Mootha, Ph.D., serves as President and Chief Executive Officer, leading a team of industry veterans with backgrounds spanning clinical development, regulatory affairs, and commercial strategy. With a commitment to addressing challenging cancers through targeted therapies, MEI Pharma continues to build on its scientific expertise as it progresses its pipeline toward potential regulatory approval and broader patient access.AI Generated. May Contain Errors. Read More MEI Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreMEIP MarketRank™: MEI Pharma scored higher than 13% of companies evaluated by MarketBeat, and ranked 899th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MEI Pharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MEI Pharma are expected to grow in the coming year, from ($5.10) to ($3.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.71% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 7.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.09 Percentage of Shares Shorted8.71% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 7.32%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.12% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MEI Pharma's insider trading history. Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MEIP Stock News HeadlinesMEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’September 11, 2025 | theglobeandmail.comMEI Pharma to change name to Lite StrategySeptember 10, 2025 | msn.comRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.October 15 at 2:00 AM | Stansberry Research (Ad)MEI Pharma Secures Loan Agreement with BitGo PrimeSeptember 4, 2025 | msn.comMEI Pharma Welcomes New Board Member Joshua RiezmanAugust 11, 2025 | theglobeandmail.comMEI Pharma files to sell 25.3M shares of common stock for holdersAugust 7, 2025 | msn.comMEI Pharma’s Strategic Shift with Litecoin TreasuryJuly 25, 2025 | theglobeandmail.comMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeJuly 22, 2025 | businesswire.comSee More Headlines MEIP Stock Analysis - Frequently Asked Questions How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.39) EPS for the quarter. When did MEI Pharma's stock split? Shares of MEI Pharma reverse split on the morning of Monday, April 17th 2023.The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), CymaBay Therapeutics (CBAY) and Jabil (JBL). Company Calendar Last Earnings5/13/2025Today10/15/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees100Year Founded2000Profitability EPS (Trailing Twelve Months)($4.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$17.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-77.00% Return on Assets-64.79% Debt Debt-to-Equity RatioN/A Current Ratio16.78 Quick Ratio16.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow0.51 Book Value$4.96 per share Price / BookN/AMiscellaneous Outstanding Shares32,838,000Free Float31,813,000Market Cap$104.72 million OptionableOptionable Beta0.38 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:MEIP) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
